Secondary Schizophrenia (173 page)

complex auditory hallucinosis,

schizophrenia,
25

SMART,
4t

29–
30

schizophrenia,
25

musical hallucinosis,
31

spectral model of,
23

Smith, K. H.,
258

in neurologic disorders,
30–
1

in substance-related states,
27–
8

smooth pursuit eye movement

epilepsy,
30

substance intoxication,
27

(SPEM),
49,
145,
147

traumatic brain injury,
30–
1

substance withdrawal,
27–
8

in normal individuals,
28

sedatives, as cause of psychosis,
116

Snyder, S. H.,
127,
130

in schizophrenia,
30

seizure disorder, antipsychotics for,

So, N. K.,
84

simple auditory hallucinosis,

398

28–
9

Soar, K.,
149

spectrum of disturbances,
28

self-medication hypothesis,
173

social cognition,
4

secondary hallucinations. See

Sem-Jacobson, C. W.,
82–
3

social skills training (SST),
413

hallucinations;
secondary

sensitization,
117–
18

soft signs, in neurologic exam,
47–
8,
52

auditory hallucinations;

secondary olfactory and

sensorimotor gating,
320

somatic
hallucinations. See tactile

gustatory hallucinations;

sensory exam, for schizophrenia,
51

hallucinations

secondary tactile

Soni, S.,
329

hallucinations; secondary

sensory gating,
108–
9

visual hallucinations

Seroquel (quetiapine fumarate),
277

Speilmeyer,
204

secondary olfactory and gustatory

serotonin 1A receptors,
67

Spellberg, B.,
234

hallucinations,
31–
4

S-estimator maps,
66

sphingolipidoses,
214–
15, 215t

cultural variables,
32

spinocerebellar ataxias (SCA),
333,

in neurological disorders,
32–
4

Sharp, F. R.,
382

353–
4

epilepsy,
32–
4

Shaw, P.,
91–
2

other disorders,
33–
4

Spitzer, R. L.,
18

in psychiatric illness,
32

Sheppard, J.,
264

Srikanth, S.,
382

other disorders,
32

Sherer, M. A.,
114

schizophrenia,
32

Srisurapanont, M.,
130

Shergill, S.,
34

secondary schizophrenia

Starkstein, S.,
198,
200

short-term memory, benzodiazepines

difference from primary

effect on,
250

statistical genetics,
290–
2

schizophrenia,
9–
11

association analysis,
291–
2

atypicality of presentation,
9

signs and symptoms,
348–
50

linkage analysis,
290–
1

other psychotic/mental disorder

cognitive symptoms,
349

statistical parametric mapping (SPM),

presence,
9

longitudinal course,
349–
50

63

temporality,
9

neurological symptoms,
349

possible causes of,
10t

psychiatric symptoms,
349

Stern, G.,
189–
90

work-up to rule out,
10t

simple auditory hallucinosis,
28–
9

Stern, Y.,
208–
9

secondary tactile hallucinations,
34–
5

Sindrup, H. H.,
90

Stevens, J. R.,
92,
94,
105–
6

discussion,
35

in neurological disorders,
34,
35

Singh, A.,
32

stimulants and psychosis

in normal individuals,
34

Singh, S. P.,
381

biological studies,
132–
3

in psychiatric disorders,
34

event-related potential technique,

single nucleotide polymorphisms

delirium,
34

132–
3

(SNPs),
290,
316

stimulants and psychosis (cont.)

sphingolipidoses,
214–
15, 215t

differentiation,
116–
17

structural imaging studies,
133

transport defects,
214–
15, 215t

laboratory evidence,
117

transcranial magnetic

treatment of psychosis in storage

drugs as cause of chronic

stimulation,
133

disorders,
222

psychosis/SZ,
119–
20

clinical characteristics

strabismus,
49

drugs as cause of psychosis,
113–
14

of amphetamine-induced

epidemiological studies on,
114–
16

psychosis,
129–
30

Strakowski, S. M.,
133–
4

future research,
122

of cocaine-induced psychosis,

Strauss, J. S.,
114

individual risk factors,
118

130–
1

nicotine use,
116

of methamphetamine-induced

Strelets, V. B.,
65

opiate use,
116

psychosis,
130,
131

striatal Fluoro-DOPA uptake,
7

risk factors,
117–
18

cocaine-induced psychosis,
132

susceptibility for developing SIP,

Stroop task,
5

conclusions,
136

117

epidemiology,
128–
9

STRPs,
290,
291

treatment,
122

ADHD,
129

structural (volumetric)

violence/suicide risk,
122
See also

amphetamine,
129

intercorrelations,
63,
66

stimulants and psychosis

cannabis,
128–
9

substance misuse, randomized

cocaine,
128–
9

structural brain imaging studies,
6–
7

controlled trials on,
408–
12

methamphetamine,
128–
9

disrupted connectivity,
7

brief interventions,
410

follow-up studies,
132

persistence of structural alterations,

case management intensity,
410

future research,
136

6

cognitive behavior therapy,
410–
11

management of psychosis,
135–
6

psychosis development in persons

future research,
411

mechanisms underlying

with prodromal symptoms,

implications for clinical practice,

sensitization,
133–
5

6–
7

411–
12

recent studies

in vivo neuroimaging studies,
6

increasing effect of existing

of amphetamine psychosis,
131

volume reduction studies,
6

treatments,
411

of cocaine-induced psychosis,
132

Structured Clinical Interview for

integrated treatment,
411

DSM-IV (SCID),
122

intervention overview,
408

research limitations,
127–
8
See also
Study of Assets and Health Dynamics

limitations,
408–
10

substance-induced psychosis

in the USA,
198

methodological criteria scoring,
408

outcomes,
408

substance abuse/withdrawal

storage disorders and psychosis

participants,
408

resemblance to SZ,
54

adult neuronal ceroid lipofuscinosis,

sample size,
408

secondary tactile hallucinations in,

219–
20,
222

studies included in,
408,
409t

35

alpha mannosidosis,
219

secondary visual hallucinations in,

succinimides,
87

cerebrotendinous xanthomatosis,

27–
8
See also

218–
19,
248–
9

suicide ideation/attempt

substance-induced

clinical features of mitochondrial

in Huntington’s Disease,
349

psychosis; substance
misuse,

disorders,
231t

in schizophrenia,
205

randomized controlled trials

glycoproteinoses,
214–
15, 215t

in substance-induced psychosis,

on

GM2-gangliosidosis type-1 (Tay

122

Sachs Disease),
216,
222

substance-induced psychosis (SIP)

in Wilson’s Disease,
341

laboratory diagnosis of storage

alcohol use,
115

sulpiride,
353

disorders,
222

amphetamine use,
115

lipid storage disorders,
214–
15, 215t

cannabis use,
119–
20

superior temporal gyrus (STG),
6

lysosomal storage disorders,
214–
15,

cocaine use,
115,
120

superior temporal sulcus face area

215t
,
216

defining,
113

(STS-FA),
373

model for psychosis secondary to

diagnosis,
120–
2

Swain-Campbell, N.,
172

storage disorders,
217f
,
218f
,

delirium,
120

220–
1, 221f
,
222

differential diagnosis,
121–
2

Swedish conscript study, on cannabis

mucopolysaccharidoses,
214–
15,

intoxication,
120–
1

use,
119–
20,
170

215t

research instruments for,

follow-up study,
171

multiple enzyme deficiencies,

122

rejection of hypothesis,
170–
1

214–
15, 215t

treatment,
122